For: | Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021; 10(3): 29-36 [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] |
---|---|
URL: | https://www.wjgnet.com/2220-6124/full/v10/i3/29.htm |
Number | Citing Articles |
1 |
Liang-Pu Luo, Ping Suo, Li-Li Ren, Hong-Jiao Liu, Yamei Zhang, Ying-Yong Zhao. Shenkang Injection and Its Three Anthraquinones Ameliorates Renal Fibrosis by Simultaneous Targeting IƙB/NF-ƙB and Keap1/Nrf2 Signaling Pathways. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.800522
|
2 |
Marília Paula de Souza Santos, Carlos Eduardo Garcez Teixeira, Ana Paula Toledo Del Rio. Mimetizadores da esclerose sistêmica. Revista Paulista de Reumatologia 2023; 22(1): 7 doi: 10.46833/reumatologiasp.2023.22.1.7-15
|
3 |
Riya Mallik, Muktashree Saha, Basab Ghosh, Nisha Chauhan, Hari Mohan, S. Senthil Kumaran, Chandan Mukherjee. Folate Receptor Targeting Mn(II) Complex Encapsulated Porous Silica Nanoparticle as an MRI Contrast Agent for Early‐State Detection of Cancer. Small 2024; doi: 10.1002/smll.202401787
|
4 |
Yue-Qi Tan, Yan-Ni Wang, Hao-Yu Feng, Zhi-Yuan Guo, Xia Li, Xiao-Li Nie, Ying-Yong Zhao. Host/microbiota interactions-derived tryptophan metabolites modulate oxidative stress and inflammation via aryl hydrocarbon receptor signaling. Free Radical Biology and Medicine 2022; 184: 30 doi: 10.1016/j.freeradbiomed.2022.03.025
|
5 |
Shaheer Farooqi, Afshan Mumtaz, Aabiya Arif, Mehwish Butt, Una Kanor, Samuel Memoh, Mohammad Aadil Qamar, Abubakr Yosufi. The Clinical Manifestations and Efficacy of Different Treatments Used for Nephrogenic Systemic Fibrosis: A Systematic Review. International Journal of Nephrology and Renovascular Disease 2023; : 17 doi: 10.2147/IJNRD.S392231
|
6 |
Gita M. Schoenberg, Viktoria Schuetz, Joanne N. Nyarangi-Dix, Steffen J. Diehl, Rafael Heiss, Boris Adamietz. Moderne Schnittbildgebung für urologische Erkrankungen. Der Urologe 2022; 61(4): 374 doi: 10.1007/s00120-022-01792-w
|
7 |
Gang Cao, Hua Miao, Yan-ni Wang, Dan-qian Chen, Xia-qing Wu, Lin Chen, Yan Guo, Liang Zou, Nosratola D. Vaziri, Ping Li, Ying-yong Zhao. Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice. Acta Pharmacologica Sinica 2022; 43(11): 2929 doi: 10.1038/s41401-022-00914-6
|
8 |
Luyao Tian, Xia Li, Haixia Ji, Qing Yu, Mingjuan Yang, Lanping Guo, Luqi Huang, Wenyuan Gao. Melanin-like nanoparticles: advances in surface modification and tumour photothermal therapy. Journal of Nanobiotechnology 2022; 20(1) doi: 10.1186/s12951-022-01698-x
|
9 |
Chang-E Yang, Yan-Ni Wang, Meng-Ru Hua, Hua Miao, Ying-Yong Zhao, Gang Cao. Aryl hydrocarbon receptor: From pathogenesis to therapeutic targets in aging-related tissue fibrosis. Ageing Research Reviews 2022; 79: 101662 doi: 10.1016/j.arr.2022.101662
|
10 |
Li-Li Ren, Xiao-Jun Li, Ting-Ting Duan, Zheng-Hai Li, Jun-Zheng Yang, Ya-Mei Zhang, Liang Zou, Hua Miao, Ying-Yong Zhao. Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities. Chemico-Biological Interactions 2023; 369: 110289 doi: 10.1016/j.cbi.2022.110289
|
11 |
Jitka Starekova, Ali Pirasteh, Scott B. Reeder. Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media. American Journal of Roentgenology 2024; 223(3) doi: 10.2214/AJR.23.30036
|
12 |
Lulu Zhuang, Chun Lian, Zehao Wang, Ximin Zhang, Zhigang Wu, Rong Huang. Breast-lesion assessment using amide proton transfer-weighted imaging and dynamic contrast-enhanced MR imaging. Radiology and Oncology 2023; 57(4): 446 doi: 10.2478/raon-2023-0051
|
13 |
Augustas Morkvenas, Egle Ezerskyte, Vaidas Klimkevicius, Zivile Jurgelene, Jonas Venius, Marius Burkanas, Arturas Katelnikovas, Vitalijus Karabanovas. Study of shape-tunable bimodal GdPO4:Eu3+ nanoparticles and their impact on Daphnia magna. Environmental Science: Nano 2024; doi: 10.1039/D4EN00574K
|
14 |
Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, Jan C. Hofmann, Reinhard Klingel, Oluwatoyosi A. Onwuemene, Christopher J. Patriquin, Huy P. Pham, Amber P. Sanchez, Jennifer Schneiderman, Volker Witt, Nicole D. Zantek, Nancy M. Dunbar. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis 2023; 38(2): 77 doi: 10.1002/jca.22043
|
15 |
Mariyam Shiruzima Adam, Shilan Jmor, Ahmed Elsayed, Noshaba Naz. Coexistence of nephrogenic systemic fibrosis and calciphylaxis in a gadolinium-naïve, chronic haemodialysis patient. BMJ Case Reports 2024; 17(2): e258482 doi: 10.1136/bcr-2023-258482
|
16 |
Yan-ni Wang, Zhi-hao Zhang, Hong-jiao Liu, Zhi-yuan Guo, Liang Zou, Ya-mei Zhang, Ying-yong Zhao. Integrative phosphatidylcholine metabolism through phospholipase A2 in rats with chronic kidney disease. Acta Pharmacologica Sinica 2023; 44(2): 393 doi: 10.1038/s41401-022-00947-x
|
17 |
Yan-Ni Wang, Hong-Jiao Liu, Li-Li Ren, Ping Suo, Liang Zou, Ya-Mei Zhang, Xiao-Yong Yu, Ying-Yong Zhao. Shenkang injection improves chronic kidney disease by inhibiting multiple renin-angiotensin system genes by blocking the Wnt/β-catenin signalling pathway. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.964370
|
18 |
Xiao-Yong Yu, Qian Sun, Ya-Mei Zhang, Liang Zou, Ying-Yong Zhao. TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.860588
|
19 |
Ying-Yong Zhao. Recent advances of gut microbiota in chronic kidney disease patients. Exploration of Medicine 2022; : 260 doi: 10.37349/emed.2022.00090
|
20 |
Ali Al Bshabshe, Wesam F. Mousa, Nashwa Nor El-Dein. An Overview of Clinical Manifestations of Dermatological Disorders in Intensive Care Units: What Should Intensivists Be Aware of?. Diagnostics 2023; 13(7): 1290 doi: 10.3390/diagnostics13071290
|
21 |
Ling Chen, Zi Ye, Danjun Wang, Jianlian Liu, Qian Wang, Chen Wang, Bing Xu, Xuezhong Gong. Chuan Huang Fang combining reduced glutathione in treating acute kidney injury (grades 1–2) on chronic kidney disease (stages 2–4): A multicenter randomized controlled clinical trial. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.969107
|